Pricing Log in Create free account
Friday 6 November 2026 Export CRBP’s income statement to Excel — free account

Corbus Pharmaceuticals Holdings, Inc.

CRBP Healthcare Biotechnology

EPS
−25.7%
Free cash flow
−78.5%

Quarter to June 2026, against a year earlier

3.05 0.19 +6.64%
Market cap
$55.3M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
3/9
Altman Z
−4.15
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.13
Sold, $m 2.72
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — 1 — 1 — — —
Sell 1 — 5 1 — — 3 — 2 1 1 —
Insider Ownership 10.55%

Capital & Financial Ratios $m

Size
Market Cap 55.32
Revenue ttm 1.54
Net income ttm (101.90)
Free cash flow ttm (86.69)
Net debt Q (117.94)
Valuation
P/E 0.00
Forward P/E (0.33) (negative: loss-making)
Price / sales 38.44 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.58
Financial health
Current ratio Q 5.71 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (40.70)
Growth
Revenue growth Q −92.09% (below 0%: shrinking)
Operating income growth Q −88.96% (below 0%: shrinking)
EPS, this year +5.12%
EPS, next year A +0.92%
Revenue, next year A −100.00% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +1.15%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −23.8×, against a ten-year median of 36.7×; over the ten years it ranged from −30.0× in 2025 to 358× in 2024.
P/S against its own 10 years 31.86%
10-year low 10-year high
P/B against its own 10 years 7.24%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 21 149 164 118
Receivables — — — —
Inventory — — — —
Other — — — —
24 153 167 123
2023 2024 2025 Q'26
Payables 3 5 2 5
ST’ Debt 16 — — —
Other 0 — — —
32 12 21 21

Compound Annual Growth %

10y 5y 3y
Sales — (14.34%) (43.24%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 32.29% 26.65% 64.74%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −1.30 Actual −1.81

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −1.80 −1.90 Miss by 0.10
Q4 FY25 −1.78 −1.25 Beat by 0.53
Q1 FY26 −1.26 −1.23 Beat by 0.03
Q2 FY26 −1.30 −1.81 Miss by 0.51
Q3 FY26 −1.45 — Reports 11 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (1.23) (1.81) — — —
’25 (1.39) (1.44) (1.90) (1.25) (5.90)
’24 (0.83) (0.90) (1.15) (0.78) (3.68)
’23 (4.24) (2.05) (2.27) (1.81) (10.31)
’22 (2.40) (3.30) (2.10) (2.61) (10.15)
’21 (4.20) (4.50) (0.60) (2.40) (11.11)
’20 (12.91) (15.62) (12.91) (3.00) (42.64)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’21 1 0 0 — 1
’20 2 0 1 1 4
’19 2 29 3 3 36
’18 1 1 1 2 5
’17 1 0 1 0 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (26) (30) — — —
’25 (16) (17) (16) (16) (64)
’24 (8) (9) (14) (11) (42)
’23 (15) (8) (7) (6) (36)
’22 (11) (12) (7) (7) (38)
’21 (22) (18) 1 (10) (48)
’20 (28) (27) (27) (18) (100)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (26) (30) — — —
’25 (16) (17) (16) (16) (64)
’24 (8) (9) (14) (11) (42)
’23 (15) (8) (7) (6) (36)
’22 (11) (12) (7) (7) (38)
’21 (22) (18) 1 (10) (48)
’20 (28) (27) (27) (18) (100)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 2 2 5 36 4 1 — — — — 2 (14.3%) 1 3 3 +58.4%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 0.00 — — — 0.00 (100.0) pt
EBT (20) (32) (56) (71) (111) (46) (42) (45) (40) (79) (102) +16.4%
EBT margin, % (1,046.29) (1,328.65) (1,154.47) (197.69) (2,826.10) (5,176.41) 0.00 0.00 0.00 0.00 0.00 +1,046.3 pt
Net income (20) (32) (56) (71) (111) (46) (42) (45) (40) (79) (102) +16.4%
Per share, $
Per share, $ Revenue 1.40 1.46 2.54 16.99 1.51 0.22 0.00 0.00 0.00 0.00 0.00 n/m
Earnings (14.71) (19.52) (29.43) (33.63) (42.64) (11.11) (10.15) (10.31) (3.68) (5.90) (6.19) (9.7%)
Cash flow (9.91) (16.64) (15.84) (21.49) (38.31) (11.77) (9.00) (8.34) (3.83) (4.84) (4.47) (7.6%)
Capex (0.26) (0.42) (1.21) (1.29) (0.19) (0.01) 0.00 0.00 0.00 0.00 0.00 (50.0%)
Free cash flow (10.16) (17.06) (17.05) (22.78) (38.50) (11.77) (9.00) (8.34) (3.83) (4.84) (4.47) (7.9%)
Book value 6.51 34.58 14.50 2.89 17.40 16.88 7.91 (1.60) 13.05 11.08 5.27 +6.1%
Shares, m 1 2 2 2 3 4 4 4 11 13 16 +28.7%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 — — — — 0.00 0.0
P/S 181.70 163.32 68.97 9.64 24.78 49.12 — — — — 38.44 82.9
P/B 38.94 6.90 12.08 56.61 2.16 1.09 — — — — 0.58 19.6
EV/Sales 174.03 137.85 60.44 9.01 7.75 (1.76) — — — — (23.77) 64.6
EV/FCF (23.89) (11.80) (9.00) (6.72) (0.30) 0.06 — — — — 0.42 (8.6)
Cash, $m
Cash, $m Operating cash flow (14) (28) (30) (46) (100) (48) (38) (36) (42) (64) (87) +18.9%
Capex 0 (1) (2) (3) 0 0 0 — — 0 0 (35.3%)
Free cash flow (14) (29) (32) (48) (100) (48) (38) (36) (42) (64) (87) +18.6%
Balance, $m
Balance, $m Working capital 9 57 26 3 60 83 48 (8) 141 146 101 +37.2%
Net debt (15) (62) (41) (23) (67) (78) (40) (5) (149) (164) (118) +30.6%
Shareholders’ equity 9 58 28 6 45 69 33 (7) 142 148 102 +36.6%
Returns, %
Returns, % ROA (130.02) (76.41) (97.70) (148.66) (146.95) (43.46) (48.66) (94.32) (43.67) (48.47) (80.85) +81.6 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (223.40) (97.21) (130.52) (424.29) (432.68) (79.80) (82.95) (341.99) (59.34) (54.18) (95.58) +169.2 pt
People
People Employees 25 47 77 141 76 41 33 19 28 36 — +4.1%
Revenue/emp, $m 0.08 0.05 0.06 0.26 0.05 0.02 0.00 0.00 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2021 · latest quarter Sep 2021

Corbus Pharmaceuticals Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
GOSS Gossamer Bio, Inc. $57.6M — (loss-making) — (loss-making) −19.59% (below 0%: shrinking) n/m +16.32% (above 0%: growing) 100.00% (282.25%) Compare
TELO Telomir Pharmaceuticals, Inc. $57.5M — (loss-making) — — n/m −45.34% (below 0%: shrinking) — 0.00% Compare
XBIT XBiotech Inc. $57.0M — (loss-making) — (loss-making) −93.33% (below 0%: shrinking) n/m +25.25% (above 0%: growing) 0.00% 0.00% Compare
CLNN Clene Inc. $56.4M — (loss-making) — (loss-making) +273.33% (above 0%: growing) n/m −16.61% (below 0%: shrinking) 71.43% (11,333.93%) Compare
XLO Xilio Therapeutics, Inc. $55.9M — (loss-making) — (loss-making) +131.22% (above 0%: growing) n/m −26.23% (below 0%: shrinking) 100.00% (18.68%) Compare
CRBP Corbus Pharmaceuticals Holdings, Inc. $55.3M — (loss-making) — (loss-making) −92.09% (below 0%: shrinking) n/m −78.52% (below 0%: shrinking) 0.00% 0.00%
BOLD Boundless Bio, Inc. $54.8M — (loss-making) — — n/m −76.90% (below 0%: shrinking) — 0.00% Compare
RNXT RenovoRx, Inc. $53.7M — (loss-making) — (loss-making) +300.75% (above 0%: growing) n/m −12.69% (below 0%: shrinking) 82.36% (303.56%) Compare
HRTX Heron Therapeutics, Inc. $53.2M — (loss-making) — (loss-making) +1.25% (above 0%: growing) n/m +78.75% (above 0%: growing) 69.28% (5.43%) Compare
Median of peers $56.2M — — +66.24% — −14.65% 76.90% (12.05%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 2 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 3.75m 2.59m 244.44
2024 4.25m 4.07m 354.35
2023 1.14m 1.36m 181.38

Ownership

Directors and executive officers, together 3.50%
Cormorant Global Healthcare Master Fund, LP 13.20%
Aberdeen Group plc 7.50%
OrbiMed Capital LLC 6.60%
Citadel Advisors 5.50%
Octagon Capital Advisors LP 5.40%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Latest News

22 Oct

Impact 3 · · GlobeNewswire

29 Sep

Impact 4 · · GlobeNewswire

17 Sep

Impact 4 ·

15 Sep

Impact 4 · · MarketBeat

14 Sep

Impact 4 · · InvestorsHub
Impact 4 ·

11 Sep

Impact 4 ·

6 Aug

Impact 3 ·

4 Aug

Impact 3 ·

28 Jul

Impact 4 ·

9 Jun

Impact 4 · · MarketBeat

1 Jun

Impact 3 · · MarketBeat

26 May

Impact 4 · · GlobeNewswire

22 May

Impact 4 · · MarketBeat

21 May

Impact 3 · · GlobeNewswire

12 May

Impact 4 · · GlobeNewswire

5 May

Impact 3 · · GlobeNewswire

22 Apr

Impact 4 · · GlobeNewswire

17 Apr

Impact 4 · · Insider Monkey

14 Apr

Impact 4 · · GlobeNewswire

7 Apr

Impact 4 · · GlobeNewswire

11 Mar

Impact 4 · · Zacks

9 Mar

Impact 4 · · GlobeNewswire
Impact 3 · · Associated Press Finance

26 Feb

Impact 4 · · MarketBeat

5 Jan

Impact 3 · · GlobeNewswire

11 Dec

Impact 4 · · MT Newswires
Impact 4 · · GlobeNewswire

10 Dec

Impact 4 · · GlobeNewswire

12 Nov

Impact 3 · · Associated Press Finance
stockrow.com/CRBP · Data as of Sep 30, 2021 · For information only; not investment advice. · © 2026 stockrow.com